Immunity against HIV/AIDS, Malaria, and Tuberculosis during Co-Infections with Neglected Infectious Diseases: Recommendations for the European Union Research Priorities
Author Summary Infectious diseases remain a major health and socioeconomic problem in many low-income countries, particularly in sub-Saharan Africa. For many years, the three most devastating diseases, HIV/AIDS, malaria, and tuberculosis (TB) have received most of the world's attention. However, in rural and impoverished urban areas, a number of infectious diseases remain neglected and cause massive suffering. It has been calculated that a group of 13 neglected infectious diseases affects over one billion people, corresponding to a sixth of the world's population. These diseases include infections with different types of worms and parasites, cholera, and sleeping sickness, and can cause significant mortality and severe disabilities in low-income countries. For most of these diseases, vaccines are either not available, poorly effective, or too expensive. Moreover, these neglected diseases often occur in individuals who are also affected by HIV/AIDS, malaria, or TB, making the problem even more serious and indicating that co-infections are the rule rather than the exception in many geographical areas. To address the importance of combating co-infections, scientists from 14 different countries in Africa and Europe met in Addis Ababa, Ethiopia, on September 9–11, 2007. The message coming from these scientists is that the only possibility for winning the fight against infections in low-income countries is by studying, in the most global way possible, the complex interaction between different infections and conditions of malnourishment. The new scientific and technical tools of the post-genomic era can allow us to reach this goal. However, a concomitant effort in improving education and social conditions will be needed to make the scientific findings effective.
Molyneux DH, Hotez PJ, Fenwick A (2005) “Rapid-impact interventions”: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2: e336. doi:10.1371/journal.pmed.0020336. doi: 10.1371/journal.pmed.0020336
[3]
Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected tropical diseases: the Global Burden of Disease framework. PLoS Negl Tropical Dis 1: e114. doi:10.1371/journal.pntd.0000114. doi: 10.1371/journal.pntd.0000114
[4]
Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, Sachs JD (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs fro HIV/AIDS, tuberculosis, and malaria. PLoS Med 3: e102. doi:10.1371/journal.pmed.0030102. doi: 10.1371/journal.pmed.0030102
Council Decision 971/2006/CE of 19/12/2006 adopting a Specific Programme for Research, Technological Development and Demonstration: ‘Cooperation’ (2007–2013). Official Journal of the European Union, L 54 of 22 February 2007, p. 30.
[7]
TDR business plan 2008–2013. Geneva, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 2007 (TDR/GEN/EN/07.1/Rev.1).
[8]
Keen J, Serghides L, Ayi K, Patel SN, Ayisi J, et al. (2007) HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med 4: e181. doi:10.1371/journal.pmed.0040181. doi: 10.1371/journal.pmed.0040181
[9]
Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. doi: 10.1056/NEJMra064142
[10]
van Riet E, Hartgers FC, Yazdanbakhsh M (2007) Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 212: 475–490. doi: 10.1016/j.imbio.2007.03.009
[11]
Elias D, Britton S, Kassu A, Akuffo H (2007) Chronic helminth infections may negatively influence immunity against tuberculosis and other diseases of public health importance. Expert Rev Anti Infect Ther 5: 475–484. doi: 10.1586/14787210.5.3.475
[12]
Dybul M (2006) Neglected tropical diseases and HIV/AIDS. Lancet 368: 1865. doi: 10.1016/S0140-6736(06)69764-X
[13]
Epstein MA (1984) Burkitt's lymphoma: clues to the role of malaria. Nature 312: 398. doi: 10.1038/312398a0
[14]
Ramaswamy M, Geretti AM (2007) Interactions and management issues in HSV and HIV coinfection. Expert Rev Anti Infect Ther 5: 231–243. doi: 10.1586/14787210.5.2.231
[15]
Prentice AM, Ghattas H, Doherty C, Cox SE (2007) Iron metabolism and malaria. Food Nutr Bull 28: S524–S539.
[16]
Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA (2007) Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 14: 1325–1334. doi: 10.2174/092986707780597934
[17]
Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, et al. (2006) Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. J Commun Dis 38: 230–245. doi: 10.1073/pnas.0506803102
[18]
Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, et al. (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 104: 16645–16650. doi: 10.1073/pnas.0704828104
[19]
Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, et al. (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39: 523–528. doi: 10.1038/ng1976
[20]
Ebensen T, Guzmán CA (2008) Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Hum Vaccin 4: 13–22. doi: 10.4161/hv.4.1.5560